La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ascendis Pharma Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Ascendis Pharma sono diminuiti a un tasso medio annuo di -21.7%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 72.7%.

Informazioni chiave

-18.5%

Tasso di crescita degli utili

-14.7%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	73.8%
Rendimento del capitale proprio	n/a
Margine netto	-154.1%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Oct 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Jun 27

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

May 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Feb 18

Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Sep 24

Ascendis Pharma: TransCon CNP Data Coming Q4

Sep 15

Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH

Aug 31

Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa

Aug 11

Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect

Aug 03

Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money

Jun 10

Ripartizione dei ricavi e delle spese

Come Ascendis Pharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:ASND Ricavi, spese e utili (EUR Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	318	-490	269	356
31 Mar 24	329	-502	265	378
31 Dec 23	267	-481	264	413
30 Sep 23	152	-602	257	431
30 Jun 23	119	-609	254	417
31 Mar 23	78	-569	240	403
31 Dec 22	51	-583	221	380
30 Sep 22	33	-482	213	337
30 Jun 22	19	-393	192	298
31 Mar 22	14	-446	170	291
31 Dec 21	8	-384	160	296
30 Sep 21	3	-416	132	491
30 Jun 21	5	-458	111	432
31 Mar 21	5	-418	96	349
31 Dec 20	7	-419	77	261
30 Sep 20	9	-360	73	50
30 Jun 20	8	-264	66	192
31 Mar 20	10	-228	56	140
31 Dec 19	13	-218	48	192
30 Sep 19	21	-170	40	179
30 Jun 19	19	-178	37	70
31 Mar 19	16	-142	31	161
31 Dec 18	11	-130	25	140
30 Sep 18	0	-132	21	130
30 Jun 18	1	-132	17	128
31 Mar 18	1	-140	15	110
31 Dec 17	2	-124	13	100
30 Sep 17	2	-106	13	92
30 Jun 17	3	-91	12	79
31 Mar 17	4	-73	12	70
31 Dec 16	5	-69	12	66
30 Sep 16	6	-64	12	59
30 Jun 16	6	-53	10	50
31 Mar 16	7	-55	10	49
31 Dec 15	8	-33	9	41
30 Sep 15	9	-26	8	36
30 Jun 15	10	-21	8	31
31 Mar 15	12	-8	8	23
31 Dec 14	14	-10	6	20
30 Sep 14	17	-2	4	15
30 Jun 14	20	0	3	15
31 Mar 14	20	3	3	13
31 Dec 13	20	4	2	13

Guadagni di qualità: ASND al momento non è redditizia.

Margine di profitto in crescita: ASND al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ASND non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 21.7% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ASND nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ASND non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 0.5% ).

Rendimento del capitale proprio

ROE elevato: Le passività di ASND superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Ascendis Pharma Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Recent updates

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

Consensus revenue estimates fall by 19%

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Consensus EPS estimates fall by 13%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

Consensus estimates of losses per share improve by 17%

President notifies of intention to sell stock

President notifies of intention to sell stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Consensus revenue estimates increase by 12%

Ascendis Pharma's Ambitious Vision 2030

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

President notifies of intention to sell stock

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

New major risk - Negative shareholders equity

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Consensus revenue estimates decrease by 11%

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Key Executive notifies of intention to sell stock

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Consensus revenue estimates increase by 24%

Independent Chairman notifies of intention to sell stock

New major risk - Financial position

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Consensus revenue estimates decrease by 14%

President notifies of intention to sell stock

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind